NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veteran John Trainer, MBA has been appointed as the Company’s Financial Officer. Additionally, Han Myint, MD has been appointed as the Chief Medical Officer.